Article Text

Download PDFPDF

P161 Case report of a systemic lupus erythematosus and antiphospholipid syndrome patient with an infiltrative tuberculosis and melanoma: features of therapeutic approaches
  1. Anastasiia Shumilova1,
  2. Tatiana Reshetnyak1,2,
  3. Fariza Cheldieva1,2,
  4. Maria Cherkasova1 and
  5. Alexander Lila1,2
  1. 1Federal State Budgetary Scientific Institution ‘Research Institute of Rheumatology named after V.A. Nasonova’, Moscow
  2. 2Federal State Budgetary Educational Institution of Further Professional Education ‘Russian Medical Academy of Continuous Professional Education’ of the Ministry of Healthcare of the Russian Federation, Rheumatology Academic Dept., Moscow, Russian Federation


Background Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiorgan tissue damage, including skin, that is frequently treated with high doses of immunosuppressive drugs. Thus, patients with SLE are at increased risk for infections (for example, tuberculosis) and malignancy. SLE and tuberculosis may have similar presentations and mimic each other; also, prior tuberculous infection may precipitate SLE in genetically predisposed individual. An increased standardized incidence ratio for non-melanoma skin cancer has been reported, however, there is no evidence of correlation between SLE and melanoma.

Methods We report a case of a patient with SLE and antiphospholipid syndrome (APS) with a moderate disease activity index (SLEDAI = 7) with infiltrative tuberculosis and melanoma.

Results A 41-year-old female patient with SLE for 22 years, was diagnosed on the basis of skin lesion, alopecia, photosensitivity, oral ulcers, arthritis, pericarditis, hemolytic anemia, leukopenia, highly positive antibodies to dsDNA, hypocomplementemia, ANF hep-2 positivity. An anamnesis of the disease and treatment tactics are presented in table 1.

Abstract P161 Table 1

Clinical and laboratory manifestations of the disease and treatment tactics

Conclusions There are no established guidelines available for treatment of tuberculosis or melanoma in SLE patients due to lack of relevant studies and management based more on physician expertise. The use of genetically engineered biological drugs can be limited due to the high risk of infection, the onset of cancer in the anamnesis, and also not fully studied in patients with comorbidity.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.